Stock Market Reviews

DMAC (DiaMedica Therapeutics Inc.) News

Get the latest news, insights, and market updates on DMAC (DiaMedica Therapeutics Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  MINNEAPOLIS, September 29, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on September 18, 2025, it granted stock options to purchase an aggregate of 490,000 shares of DiaMedica’s common stock to five newly hired non-executive employees whose employment commenced in August and September 2025.
  Sep 29, 2025 - $DMAC
• DiaMedica Therapeutics, Inc. (DMAC) is a Great Momentum Stock: Should You Buy?
  Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Sep 17, 2025 - $DMAC
• After Golden Cross, DiaMedica Therapeutics, Inc. (DMAC)'s Technical Outlook is Bright
  When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
  Sep 9, 2025 - $DMAC
• Wall Street Analysts Believe DiaMedica Therapeutics (DMAC) Could Rally 100.81%: Here's is How to Trade
  The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to a 100.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Sep 8, 2025 - $DMAC
• DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$43.1m
  In the last year, multiple insiders have substantially increased their holdings of DiaMedica Therapeutics Inc...
  Sep 8, 2025 - $DMAC
• DiaMedica Therapeutics to Participate in Upcoming Investor Conferences
  MINNEAPOLIS, September 05, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction, and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in two upcoming investor conferences in New York City.
  Sep 5, 2025 - $DMAC
• DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference
  MINNEAPOLIS, September 02, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that Rick Pauls, President and CEO, and Dave Wambeke, Chief Business Officer, will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference being held in New York City from September 3-5, 2025.
  Sep 2, 2025 - $DMAC
• What Makes DiaMedica Therapeutics, Inc. (DMAC) a Strong Momentum Stock: Buy Now?
  Does DiaMedica Therapeutics, Inc. (DMAC) have what it takes to be a top stock pick for momentum investors? Let's find out.
  Aug 28, 2025 - $DMAC
• Does DiaMedica Therapeutics (DMAC) Have the Potential to Rally 114.06% as Wall Street Analysts Expect?
  The mean of analysts' price targets for DiaMedica Therapeutics (DMAC) points to an 114.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
  Aug 19, 2025 - $DMAC
• DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
  MINNEAPOLIS, August 12, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today provided a business update and reported financial results for the second quarter ended June 30, 2025. Management will host a conference call Wednesday, August 13, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and second quarter 20
  Aug 12, 2025 - $DMAC